Julie Zhen Qin Wu

Array ( [id] => 12092557 [patent_doc_number] => 20170349650 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-07 [patent_title] => 'IMMUNOGLOBULINS WITH REDUCED AGGREGATION' [patent_app_type] => utility [patent_app_number] => 15/596867 [patent_app_country] => US [patent_app_date] => 2017-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28671 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15596867 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16376392 [patent_doc_number] => 20200325234 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-15 [patent_title] => IMMUNE-BASED TREATMENT OF KRAS-VARIANT CANCER PATIENTS [patent_app_type] => utility [patent_app_number] => 16/096316 [patent_app_country] => US [patent_app_date] => 2017-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19129 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16096316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15946153 [patent_doc_number] => 10660955 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-05-26 [patent_title] => Cancer methods [patent_app_type] => utility [patent_app_number] => 15/481018 [patent_app_country] => US [patent_app_date] => 2017-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 22 [patent_no_of_words] => 37683 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15481018 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12217432 [patent_doc_number] => 20180055791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-03-01 [patent_title] => 'LOW DOSAGE SEROTONIN 5-HT2A RECEPTOR AGONIST TO SUPPRESS INFLAMMATION' [patent_app_type] => utility [patent_app_number] => 15/478437 [patent_app_country] => US [patent_app_date] => 2017-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 10536 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15478437 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11757316 [patent_doc_number] => 20170204182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-07-20 [patent_title] => 'VH-VL-INTERDOMAIN ANGLE BASED ANTIBODY HUMANIZATION' [patent_app_type] => utility [patent_app_number] => 15/475440 [patent_app_country] => US [patent_app_date] => 2017-03-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 33046 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15475440 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13425179 [patent_doc_number] => 20180264132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-20 [patent_title] => Combined Tissue Resonance Suppression Therapy and Autologous Polyvalent Biological Vaccine [patent_app_type] => utility [patent_app_number] => 15/462857 [patent_app_country] => US [patent_app_date] => 2017-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7744 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15462857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11963615 [patent_doc_number] => 20170267768 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'Protein A Binding Polypeptides, Anti-EphA2 Antibodies and Methods of Use Thereof' [patent_app_type] => utility [patent_app_number] => 15/457857 [patent_app_country] => US [patent_app_date] => 2017-03-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 19830 [patent_no_of_claims] => 65 [patent_no_of_ind_claims] => 8 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15457857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11706286 [patent_doc_number] => 20170174785 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-22 [patent_title] => 'COMPOSITION COMPRISING ANTIBODY THAT BINDS TO DOMAIN II OF HER2 AND ACIDIC VARIANTS THEREOF' [patent_app_type] => utility [patent_app_number] => 15/450509 [patent_app_country] => US [patent_app_date] => 2017-03-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 25913 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15450509 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866188 [patent_doc_number] => 20170233473 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'C10RF32 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER' [patent_app_type] => utility [patent_app_number] => 15/445208 [patent_app_country] => US [patent_app_date] => 2017-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 32 [patent_figures_cnt] => 32 [patent_no_of_words] => 62076 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15445208 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11668479 [patent_doc_number] => 20170157199 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-08 [patent_title] => 'LYTIC-PEPTIDE-HER2/NEU (HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2) LIGAND CONJUGATES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/433887 [patent_app_country] => US [patent_app_date] => 2017-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 26965 [patent_no_of_claims] => 71 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15433887 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16336569 [patent_doc_number] => 10787514 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => CD33 antibodies and use of same to treat cancer [patent_app_type] => utility [patent_app_number] => 15/411947 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 3 [patent_no_of_words] => 18786 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11977639 [patent_doc_number] => 20170281793 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-10-05 [patent_title] => 'ANTI-TEM1 ANTIBODIES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/411938 [patent_app_country] => US [patent_app_date] => 2017-01-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 29617 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15411938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13774861 [patent_doc_number] => 20190000969 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-03 [patent_title] => NOVEL ANTI-UPK1B ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/065064 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 52437 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -38 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13826655 [patent_doc_number] => 20190016812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => NOVEL ANTI-TNFSF9 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/065063 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -42 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065063 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837515 [patent_doc_number] => 20190022242 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => NOVEL ANTI-MMP16 ANTIBODIES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/065059 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55730 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -39 [patent_words_short_claim] => 12 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16065059 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13622135 [patent_doc_number] => 20180362619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-20 [patent_title] => VARIANT ANTIBODIES FOR SITE-SPECIFIC CONJUGATION [patent_app_type] => utility [patent_app_number] => 16/061646 [patent_app_country] => US [patent_app_date] => 2016-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16061646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11956102 [patent_doc_number] => 20170260253 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-14 [patent_title] => 'CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES' [patent_app_type] => utility [patent_app_number] => 15/357545 [patent_app_country] => US [patent_app_date] => 2016-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 31991 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15357545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16183544 [patent_doc_number] => 10716837 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-07-21 [patent_title] => Methods and compositions relating to P62 for the treatment and prophylaxis of cancer [patent_app_type] => utility [patent_app_number] => 15/340118 [patent_app_country] => US [patent_app_date] => 2016-11-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 13 [patent_no_of_words] => 12420 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15340118 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11604394 [patent_doc_number] => 20170121693 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-05-04 [patent_title] => 'NUCLEOBASE EDITORS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/331852 [patent_app_country] => US [patent_app_date] => 2016-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 138 [patent_figures_cnt] => 138 [patent_no_of_words] => 77935 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15331852 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11443251 [patent_doc_number] => 20170044271 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-02-16 [patent_title] => 'NOVEL ANTI-DPEP3 ANTIBODIES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 15/331282 [patent_app_country] => US [patent_app_date] => 2016-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 51 [patent_figures_cnt] => 51 [patent_no_of_words] => 48479 [patent_no_of_claims] => 31 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15331282 [rel_patent_id] =>[rel_patent_doc_number] =>)